26 results about "Oxymatrine" patented technology

The invention relates to application of oxymatrine in preparation of a medicine for treating a patient suffering from erythroderma psoriasis and the like.

The invention provides a monascus strain ZX-99 capable of expressing multiple beneficial active substances and application of the monascus strain ZX-99, and belongs to the technical field of microorganisms. The preservation number of the monascus strain ZX-99 provided by the invention is CGMCC No.40962, the strain does not produce citrinin (the detection limit is 25 mg / kg), and compared with other monascus cheese and commercially available mould cheese, the prepared cheese sample has the advantages that the content of citrinin in the cheese sample is greatly reduced, and the content of citrinin in the cheese sample is greatly reduced. Substances such as oxymatrine, bufalin, azadirachtin, gamma-aminobutyric acid, hydroxybenzylamine, maleic acid, maltotriose, maltotetraose and diacetyl are enriched in the monascus cheese ZX-99, and the monascus cheese ZX-99 is expected to be used for developing biological functional dairy products or compounding flavor strains.

The present application relates to the application of traditional Chinese medicine active ingredient composition and its preparation in synergistic anti-tumor of PD-1 inhibitor. The traditional Chinese medicine active ingredient composition is a composition of oxymatrine and astragaloside B. The combination of the two can improve the anti-tumor effect of PD-1 inhibitor. In addition, it can also be used in the form of preparation to realize in vivo drug delivery in cooperation with its pharmaceutically acceptable carrier. The carrier can be selected from iron-based MOF and liposome, etc. to realize the co-loading of oxymatrine and astragaloside B with different polarity and efficient drug delivery. The iron-based MOF carrier has the advantages of high drug loading capacity and Fe ion which can cooperate with astragaloside B to improve the activity of tumor infiltrating T cells. The ferromagnetism and platelet membrane modification can also precisely target tumor tissue. The preparation technology of liposome is mature, which is conducive to industrialized production and has broad prospects for clinical transformation. The combination of the two with PD-1 inhibitor can significantly improve the anti-tumor effect of PD-1 inhibitor.

The invention discloses a novel application of oxymatrine in improving psoriasis symptoms by activating PPP2CA to inhibit ERalpha activity. The novel application comprises the following steps: animal experiments; cell experiments; determining the activity of the CCK-8 cell; carrying out Giemsa staining; the ELISA kit is used for detecting inflammatory cytokines IL-17 and IL-23; carrying out DIA proteomics; carrying out PPP2CA target verification; a PPP2CA siRNA knockout experiment is carried out; a PPP2CA overexpression plasmid experiment is carried out; evaluating the curative effect of the PPP2CA inhibitor; chemical proteomics; molecular docking; determining the enzyme activity of the PPP2CA; carrying out a thermal drift experiment (CETSA) / Western Blot experiment; phosphorylated proteomics; an estrogen signal channel key protein siRNA knock-down experiment; determining the ERalpha activity through a dual-luciferase reporter gene experiment; and statistical analysis. According to the invention, oxymatrine can be promoted to directly activate PPP2CA, so that phosphorylation in estrogen signal cascade is reduced, and the activity of an estrogen receptor alpha (ER alpha) is reduced.

The invention relates to a double-drug liposome co-carrying oxymatrine and an STING agonist prodrug as well as a preparation method and application of the double-drug liposome. The double-drug liposome comprises a drug carrier and oxymatrine, wherein the drug carrier consists of a membrane material; the oxymatrine is loaded in a hydrophilic inner cavity of the carrier; the membrane material is prepared from distearoyl phosphatidylcholine, distearoyl phosphatidyl ethanolamine-polyethylene glycol and a cholesterol-STING agonist prodrug conjugate; the cholesterol-STING agonist prodrug conjugate is a conjugate formed by coupling an STING agonist prodrug with cholesterol through a chemical bond. According to the invention, the traditional Chinese medicine active component oxymatrine and the STING agonist prodrug are creatively integrated into the same liposome, so that synergistic controlled release and mechanism complementation can be realized; wherein the STING prodrug is embedded into the carrier in a chemical bond coupling manner, so that drug leakage caused by physical entrapment is avoided, the acute toxicity of the free STING agonist is remarkably reduced, and meanwhile, the innate immune activation capability of the free STING agonist is enhanced.

The present invention discloses a multifunctional thermosensitive sustained-release hydrogel, its preparation method, and its use in the preparation of antipruritic and analgesic preparations. The present invention utilizes microspheres formed by a composite of hyaluronic acid and quaternary ammonium salt chitosan. These microspheres are sequentially mixed with a drug, a solubilizing agent-dissolved cooling substance, and poloxamer 407 using a simpler magnetic stirring method. This multifunctional thermosensitive sustained-release hydrogel is prepared without the use of a thickener. The hydrogel prepared by the present invention exhibits a strong cooling odor and sustained-release effect, along with good biocompatibility. When the drug used is an antipruritic and analgesic substance, such as oxymatrine, the hydrogel also has therapeutic and analgesic effects for non-histamine-dependent pruritus.

The application provides mefenamic acid-oxymatrine co-amorphous substance and a preparation method and application thereof, and belongs to the technical field of medicines. The mefenamic acid-oxymatrine co-amorphous substance is composed of mefenamic acid and oxymatrine with a molar ratio of 1:(0.5-3), and the co-amorphous substance is prepared by a grinding method or a solution crystallization method. The mefenamic acid-oxymatrine co-amorphous substance provided by the application has good stability, can significantly improve the solubility of mefenamic acid in water, thereby improving the bioavailability of mefenamic acid, and can also have synergistic effect.

The invention belongs to the technical field of biopesticides, and particularly relates to a biopesticide for preventing and treating tea lesser leafhopper, the active component of the biopesticide is formed by compounding metarhizium anisopliae and oxymatrine or tenvermectin; wherein the metarhizium anisopliae is a metarhizium anisopliae CQMa421 mother drug with a concentration of 15 billion spores per gram. According to the invention, the microbe source metarhizium anisopliae with insecticidal activity is reasonably compounded with other biopesticide components, and compared with the singly used source metarhizium anisopliae, the control effect on tea lesser leafhopper can be improved.

The application belongs to the technical field of biological medicine, and specifically discloses application of seco-oxymatrine in preparation of an antidepressant, wherein the antidepressant further contains a pharmaceutically acceptable carrier; the antidepressant is one of an oral preparation, an inhalant and an injection; the oral preparation is one of a suspension, an emulsion, a solution, a powder, a tablet, a granule and a capsule. When seco-oxymatrine is used as an effective component of the antidepressant, the depressive behavior of a LPS-induced depressive model mouse can be effectively improved.

The invention discloses a method for detecting effective components of a cervicitis treatment composition, which adopts high performance liquid chromatography for detection, and the chromatographic conditions are as follows: a chromatographic column is a C18 chromatographic column; the detection wavelength is 207 nm; a mobile phase A is a 0.2% phosphoric acid aqueous solution, a mobile phase B is acetonitrile, gradient elution is adopted, the mobile phase proportion is volume percent, and the elution procedure is as follows: 0-5 min, the mobile phase A is 100%, and the mobile phase B is 0%; the mobile phase A accounts for 100%-96% and the mobile phase B accounts for 0%-4% in 5-40 min; 40-60 min, the mobile phase A is 88%-58%, and the mobile phase B is 12%-42%; the mobile phase A accounts for 92% and the mobile phase B accounts for 8% in 60-80 min. The method disclosed by the invention can be used for simultaneously determining the components such as sophocarpidine, sophoridine, oxymatrine and amygdalin in the cervicitis composition, is convenient to operate, accurate in detection result and good in stability, and has very high practicability.

The invention belongs to the technical field of matrine preparation, and particularly relates to a method for converting sophocarpine in radix sophorae flavescentis percolate into matrine. Comprising the following steps: adding Na2SO3 into the radix sophorae flavescentis percolate, reacting at the temperature of 20-25 DEG C, namely near room temperature, and converting sophocarpine in the radix sophorae flavescentis percolate into sophocarpine; the mass volume ratio of the Na2SO3 to the radix sophorae flavescentis percolate solution is (0.022 g to 0.024 g): 1 mL. According to the method, efficient conversion of sophocarpine into sophocarpidine can be achieved by accurately controlling the adding amount of Na2SO3, the whole conversion process is mild, a catalyst and a high-temperature environment do not need to be added, and the efficiency of converting sophocarpidine into sophocarpidine is effectively improved.

The invention discloses application of oroxin B in preparation of a medicine for promoting osteogenic differentiation of bone marrow mesenchymal stem cells, hydrogel of the oroxin B and a preparation method of the hydrogel, and belongs to the technical field of biomedical materials. The invention firstly provides application of oroxin B in preparation of a medicine for promoting osteogenic differentiation of bone marrow mesenchymal stem cells. The invention also provides a self-assembled polypeptide hydrogel loaded with the oroxin B. The hydrogel is obtained by combining the oroxin B with the self-assembled polypeptide with a specific sequence (SEQ ID No.1) and carrying out mild physical blending and incubation. The hydrogel forms a three-dimensional nanofiber network, can entrap and continuously release oroxin B in situ, not only can effectively collect bone marrow mesenchymal stem cells, but also can provide an ideal microenvironment for proliferation and osteogenic differentiation of the bone marrow mesenchymal stem cells, and remarkably up-regulate osteogenic related gene expression, so that bone defect repair is expected to be accelerated.

The invention belongs to the technical field of hydrogel and fruit preservation, and relates to glycyrrhizic acid / oxymatrine / berberine co-assembled hydrogel as well as a preparation method and application thereof. The preparation method comprises the following steps: dissolving glycyrrhizic acid in water, continuously stirring at 70-90 DEG C until the glycyrrhizic acid is completely dissolved to obtain a glycyrrhizic acid solution, adding oxymatrine, then adding berberine, uniformly stirring, and then cooling to room temperature to form glycyrrhizic acid / oxymatrine / berberine co-assembled hydrogel; the molar ratio of oxymatrine to glycyrrhizic acid is below 1: 2, and the molar ratio of glycyrrhizic acid to berberine is 12: (0.25-6.0). According to the invention, glycyrrhizic acid, oxymatrine and berberine are taken as raw materials, and are co-assembled to form the hydrogel; the fruit preservative is sprayed before picking, is easy to adhere to and accumulate on the surfaces of fruits, enhances the fresh-keeping and antibacterial capabilities, improves the fresh-keeping effect of the fruits, and reduces the risk of physical damage caused by post-picking treatment at the same time.

The application provides a flufenamic acid-oxymatrine co-amorphous substance and a preparation method and application thereof, and belongs to the technical field of medicines.The flufenamic acid-oxymatrine co-amorphous substance is composed of flufenamic acid and oxymatrine in a molar ratio of 3:1-1:3, and the co-amorphous substance is prepared by a grinding method or a solution crystallization method.The flufenamic acid-oxymatrine co-amorphous substance has good stability, can significantly improve the solubility of flufenamic acid in water, thereby improving the bioavailability of flufenamic acid, and can also have synergistic effects.

This invention provides the application of oxymatrine in the preparation of drugs that inhibit jellyfish toxins, belonging to the field of biomedical technology. Screening experiments were conducted on various drugs, revealing that oxymatrine (OMT) was more effective than other drugs in antagonizing jellyfish toxins without exhibiting cytotoxicity. Further research showed that oxymatrine can reduce H9C2 cell apoptosis, antagonize apoptosis and oxidative damage induced by jellyfish toxins, improve the survival rate of mice after injection of jellyfish toxins, and improve cardiac tissue damage caused by jellyfish toxins in mice. It shows great potential in the preparation of jellyfish toxin antagonistic drugs and can serve as a candidate drug for treating jellyfish stings.

The invention provides a flufenamic acid-aloperine co-amorphous substance as well as a preparation method and application thereof, and belongs to the technical field of medicines. The flufenamic acid-aloperine co-amorphous substance is prepared from flufenamic acid and aloperine in a molar ratio of (3: 1)-(1: 3), and the co-amorphous substance is prepared by a grinding method or a solution crystallization method. The flufenamic acid-aloperine co-amorphous substance provided by the invention has good stability, and the solubility of flufenamic acid in water can be remarkably improved, so that the bioavailability of the flufenamic acid is improved, and the flufenamic acid-aloperine co-amorphous substance can achieve synergistic interaction.

The invention belongs to the technical field of biomedical materials. The invention provides a preparation method of an ultrasonic piezoelectric composite scaffold for promoting bone repair, which comprises the following steps: mixing oxymatrine and saikoside C as a mixed medicine; the mixed medicine and a stent obtained by sintering hollow barium titanate nanoparticles and hydroxyapatite powder and performing high-pressure polarization treatment are jointly placed in water, after adsorption equilibrium is achieved through stirring, the free mixed medicine is removed, and the ultrasonic piezoelectric composite stent for promoting bone repair is obtained. Wherein the weight ratio of the oxymatrine to the saikoside C is (3-5): 1, and the weight ratio of the hollow barium titanate nanoparticles to the hydroxyapatite powder is 1: 1. According to the invention, the effect of the stent material and the carried medicine on promoting bone repair is fully exerted, the synergistic effect of the material and the carried medicine on promoting osteogenic differentiation is realized, and the stent has a good application prospect.

The application discloses a quality control method of radix stephaniae tetrandrae decoction pieces, adopts liquid chromatography-mass spectrometry to detect the efficacy components in the radix stephaniae tetrandrae decoction pieces, and the efficacy components include any one or several of tetrandrine, fangchinoline, cycilanol, stepholidine, oxystepholidine, stephaoxime, corynoxeine, miliradin and oxymatrine. The specific detection condition can detect multiple efficacy components in the radix stephaniae tetrandrae decoction pieces, which is helpful for comprehensively controlling the quality of the radix stephaniae tetrandrae decoction pieces, and finding the possibility of replacing wild radix stephaniae tetrandrae through efficacy evaluation. In addition, the thin layer chromatography is used to identify the radix stephaniae tetrandrae decoction pieces before detection, and the identification sensitivity can be improved by adjusting the thin layer chromatography condition.

The invention discloses an oxymatrine-caffeic acid co-crystal and a preparation method thereof, and belongs to the technical field of natural product co-crystallization, the molecular formula of oxymatrine-caffeic acid is C15H25N2O2.C9H7O4. 3H2O, the crystal structure belongs to a monoclinic system, the preparation method of the oxymatrine-caffeic acid co-crystal comprises the following steps: respectively weighing oxymatrine and caffeic acid according to a molar ratio, and adding the oxymatrine and the caffeic acid into a reaction kettle; and mixing the two components, and placing the mixture in a glass container. And then, adding a proper amount of solvent into the container, filtering the obtained oxymatrine-caffeic acid mixed solution, standing, volatilizing and crystallizing to obtain the oxymatrine-caffeic acid eutectic. The oxymatrine-caffeic acid eutectic prepared by the invention can effectively improve the dissolution performance of an insoluble natural product caffeic acid and improve the bioavailability of the caffeic acid. The preparation method is simple and easy for industrial development and production, and has a good application prospect.

The invention relates to the technical field of preparation of drug-resistant drugs, and discloses a pharmaceutical composition for reducing drug resistance of liver cancer cells, which is prepared from the following components in parts by mass: 10 to 20 parts of oxymatrine, 5 to 15 parts of curcumin, 8 to 15 parts of ginsenoside Rg38, 3 to 8 parts of sorafenib, 5 to 12 parts of quercetin and 3 to 8 parts of oridonin. Different components in the pharmaceutical composition have a synergistic effect and jointly play a role in reducing the drug resistance of the liver cancer cells, so that the drug resistance of the liver cancer cells can be effectively reduced, and the safety is high.

The invention discloses a fingerprint spectrum detection method for yin-nourishing and stomach-clearing granules based on multi-component substances, and belongs to the technical field of quality control of traditional Chinese medicine preparations. According to the method, a high performance liquid chromatography-mass spectrometry technology is adopted, 5-hydroxymethylfurfural, oxymatrine, neomangiferin, mangiferin, forsythiaside A, rutin, tectoridin, naringin, iridoside, naringenin and irisflorentin are taken as reference substances, different batches of test products are detected by optimizing extraction conditions and chromatographic parameters, and the fingerprint spectrum is successfully constructed. The method is simple and easy to implement, high in precision and good in reproducibility, multi-component synchronous identification can be achieved at a time, the detection efficiency is greatly improved, and time and cost are saved; quality monitoring can be accurately, rapidly and simultaneously carried out on a plurality of characteristic components of the Yin-nourishing and stomach-clearing granules, and a powerful guarantee is provided for controlling the quality and ensuring the clinical curative effect of the Yin-nourishing and stomach-clearing granules.

The invention relates to a biomedical functional material and nano-drug delivery technology, in particular to dual-response nano-hydrogel for promoting healing of chronic wound surfaces of diabetes mellitus, a preparation method and application. According to the hydrogel, chitosan / sodium tripolyphosphate / hyaluronic acid nanoparticles are constructed to stably deliver miR-144-5p, oxymatrine is synergistically entrapped in a gelatin-TG enzyme cross-linked hydrogel matrix, in-situ gelling under the body temperature condition is achieved, and difunctional drugs are sequentially released. Animal experiments prove that the composition can significantly accelerate wound closure, improve VEGF and CD31 expression and reconstruct a dermal vascular network, has good biocompatibility and controlled release performance, and has wide clinical application prospects.

The present application relates to biomedical functional materials and nano drug delivery technology, and particularly relates to a double-response nano hydrogel for promoting chronic wound healing of diabetes, a preparation method and application. The hydrogel is stable in delivery of miR-144-5p by constructing chitosan / sodium tripolyphosphate / hyaluronic acid nanoparticles, and is synergistically loaded with oxymatrine in a gelatin-TG enzyme crosslinking hydrogel matrix, so that in-situ gelation and sequential release of double functional drugs are realized under body temperature. Animal experiments prove that the composition can significantly accelerate wound closure, improve VEGF and CD31 expression and reconstruct dermal vascular network, and has good biocompatibility and controlled release performance, and has a wide clinical application prospect.

This invention provides a high-yield cultivation method for rice-Houttuynia cordata rotation, belonging to the field of crop rotation technology. The method provided by this invention can significantly improve the yield and commercial quality of both rice and Houttuynia cordata, reduce the input of chemical fertilizers, pesticides, and irrigation water, and lower the intensity of farming labor and production costs. Simultaneously, it effectively improves soil physical and chemical properties, increases soil organic matter content and fertilizer retention capacity, reduces agricultural non-point source pollution, and realizes the circular utilization of agricultural resources. It has broad application prospects and good ecological and economic benefits in rice-herbicide rotation areas.

The present invention belongs to the field of crop genetic breeding and relates to the cultivation of plants with high matrine and oxymatrine content. Specifically disclosed is a transcription factor that positively regulates matrine and oxymatrine in plants. The nucleotide sequence of the transcription factor has 90% similarity to the sequence shown in SEQ ID No. 1. Furthermore, the nucleotide sequence of the transcription factor is shown in SEQ ID No. 1. The present invention constructs a transcription factor of Sophora flavescens ( StNAC46 Gene) overexpression vector, which was genetically transformed to confirm StNAC46 The gene can increase the accumulation of matrine and oxymatrine in plants, providing a new idea for cultivating and producing Sophora flavescens with high matrine and oxymatrine content.

The present application relates to a polysaccharide modified drug phospholipid complex, wherein the drug phospholipid complex is prepared from a drug and a phospholipid, the drug includes oxymatrine and glycyrrhizin, and the polysaccharide modification is that the drug phospholipid complex is first modified by chitosan, and then the drug phospholipid complex coated with chitosan is modified by hyaluronic acid. The polysaccharide modified drug phospholipid complex of the present application can enhance the drug accumulation in tumor cells through synergistic effect and active targeting, and significantly improve the anti-tumor effect of the drug.